The legionella testing market is anticipated to be valued at US$ 355.1 million by 2024. The market valuation is estimated to be US$ 910 million by 2034, projected at a CAGR of 9.9%.

https://www.globenewswire.com/en/news-release/2024/04/01/2855294/0/en/Legionella-Testing-Market-Poised-for-Robust-Growth-Projected-to-Attain-US-910-Million-by-2034-with-a-Noteworthy-9-9-CAGR-Future-Market-Insights-Inc.html

The legionella testing market is experiencing a surge in awareness of Legionnaires' disease, that is needed to mitigate its risks. Regulatory mandates in various industries, like healthcare, hospitality, and industrial sectors, are driving the demand for legionella testing services.

Advancements in testing technologies, like rapid testing kits and molecular techniques, help in the enhancement, accuracy and efficiency of legionella detection, further fueling the expansion of the market.

The expansion into emerging markets, sees growth in awareness of Legionnaires' disease that has limited access to testing services. Testing companies tap into new revenue streams and lead to contribution and improvement in public health outcomes.

Integrating legionella testing services into comprehensive water management programs present an opportunity by enhancing risk mitigation efforts and thus ensure regulatory compliance across various industries.

Several threats pose challenges to the legionella testing market like complexity of testing processes, cost constraints for smaller facilities, and the emergence of new strains of legionella bacteria.

Misinformation or stigma surrounding Legionnaires' disease lead to discouragement of some facilities from proactively testing or disclosing outbreaks, which lead to underreporting and thus hamper prevention efforts.

Key Takeaways from the Legionella Testing Market Study

Under type, the urine antigen testing (UAT) registered to expand at 9.7% CAGR by 2034.
The United Kingdom is estimated to register at a CAGR of 11.1% by 2034.
China experiences significant growth, projected at a CAGR of 10.5% by 2034.
Based on end user, the clinical laboratories segment is anticipated to expand at 9.5% CAGR by 2034.
“The growth in awareness of Legionnaires' disease and the need for effective risk management strategies is one significant driver for the Legionella Testing market,” comments Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Competitive Landscape from the Legionella Testing Market:

Established players offer a wide a range of testing services and solutions Innovative startups have started leveraging technological advancements to disrupt traditional testing methods.

Competition is majorly fueled by factors such as regulatory compliance, technological innovation, and customer-centricity. Some of the key developments are:

In December 2021, Pace Analytical Services acquired Special Pathogens Laboratory, a specialist used in Legionella testing, detection, remediation, and prevention.
In April 2018, Phigenics Research and Innovation Lab introduced the Next Day Legionella PCR test, that leveraged the patented Phigenics Validation Test (PVT) TimeZero method required for rapid detection of Legionella DNA via PCR.
Click Here to Request Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-19279

Top Companies Profiled from the Legionella Testing Market:

Quidel Corporation
Abbott (Alere)
Merck KGaA
Bio-Rad Laboratories Inc.
Thermo Fisher Scientific Inc.
Pro-lab Diagnostics Inc.
bioMerieux
IDEXX Corporation
Eurofins Scientific
Beckman Coulter Inc.
More Valuable Insights Available